CYRX Stock Analysis: Cryoport | NASDAQ

Cryogenic Shippers, Cryogenic Freezers, Biostorage Services, Cell Cryopreservation

Total Rating 45

Safety 62

Buy Signal 0.47

Integrated Freight & Logistics
Industry Rotation: -2.4

Market Cap: 911M
Avg Turnover: 13.2M

Risk 3d forecast

Volatility51.5%

VaR 5^th Pctl7.90%

VaR vs Median-6.36%

Reward TTM

Sharpe Ratio1.54

Rel. Str. IBD95.9

Rel. Str. Peer Group90.5 pctl

Character TTM

Beta1.614

Beta Downside1.279

Hurst Exponent0.515

Choppyness51.7%

Drawdowns 3y

Max DD75.04%

CAGR/Max DD0.26

CAGR/Mean DD0.48

EPS (Earnings per Share)

Last SUE: 0.00
Qual. Beats: 0

Revenue

Rev. CAGR: -7.73%
Rev. Trend: -80.4%

Last SUE: 0.10
Qual. Beats: 0

Warnings

High Debt/EBITDA With Thin Interest Coverage

High Debt While Negative Cash Flow

Interest Coverage Ratio Critical

Altman Z'' In Financial Distress Zone

Tailwinds

Rs Leader

Idiosyncratic Leader

Seasonality 11.7 years of data

Jan -1.6% 38

Feb -6.8% 22

Mar +1.4% 10

Apr -0.4% 10

May +13.1% 20

Jun +11.2% 57

Jul +1.9% 18

Aug +4.0% 20

Sep +0.2% 7

Oct -12.3% 29

Nov +1.7% 11

Dec +2.6% 14

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: CYRX Cryoport

Cryoport, Inc. (NASDAQ: CYRX) is a temperature-controlled supply chain solutions provider serving the biopharma/pharma, animal health, and reproductive medicine markets globally. Founded in 1999 and headquartered in Brentwood, Tennessee, the company operates through two main segments: Life Sciences Services (offering logistics, biostorage, bioservices, and cryopreservation) and Life Sciences Products (manufacturing cryogenic freezers, dewars, and accessories sold via direct sales and distributors).

The companys product portfolio includes the Cryoport Express Shippers, Cryoport Elite, the Express Cryogenic HV3 Shipping System, the Smartpak Condition Monitoring System, Tec4Med IoT-based monitoring solutions, and the MVE Fusion and MVE Vario cryogenic freezer systems. Its service offerings span controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, Qualified Person drug product release, and IntegriCell services covering apheresis collection, cryopreservation, and related logistics.

The cold chain logistics sector for biopharmaceuticals has grown in importance due to the increasing development of temperature-sensitive biologics, cell therapies, and gene therapies, many of which require ultra-low temperature storage and transport (often at or below -150°C) to maintain product viability. Cryoports integrated products plus services model combines proprietary cryogenic hardware with recurring logistics and storage services, creating a sticky offering tied to the lifecycle of advanced therapy developers and biobanks.

Headlines to Watch Out For

Cell and gene therapy demand drives biopharma logistics revenue growth
Acquisition integration costs pressure margins amid revenue scaling
Competition intensifies in temperature-controlled pharma logistics market

Piotroski VR-10 (Strict) 2.0

Net Income: -36.3m TTM > 0 and > 6% of Revenue
FCF/TA: -0.03 > 0.02 and ΔFCF/TA 1.92 > 1.0
NWC/Revenue: 128.3% < 20% (prev 166.4%; Δ -38.11% < -1%)
CFO/TA 0.01 > 3% & CFO 7.97m > Net Income -36.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.08 > 1.5 & < 3
Outstanding Shares: last quarter (50.4m) vs 12m ago 0.37% < -2%
Gross Margin: 47.08% > 18% (prev 45.73%; Δ 1.35% > 0.5%)
Asset Turnover: 25.61% > 50% (prev 28.96%; Δ -3.35% > 0%)
Interest Coverage Ratio: -13.69 > 6 (EBIT TTM -28.9m / Interest Expense TTM 2.11m)

Altman Z'' 0.70

A: 0.32 (Total Current Assets 460.2m - Total Current Liabilities 221.0m) / Total Assets 756.2m
B: -0.94 (Retained Earnings -707.7m / Total Assets 756.2m)
C: -0.04 (EBIT TTM -28.9m / Avg Total Assets 728.0m)
D: 1.85 (Book Value of Equity 490.7m / Total Liabilities 265.5m)
Altman-Z'' = 0.70 = B

Beneish M -2.73

DSRI: 1.40 (Receivables 36.5m/28.4m, Revenue 186.5m/202.7m)
GMI: 0.97 (GM 45.73% / 47.08%)
AQI: 1.10 (AQ_t 0.27 / AQ_t-1 0.24)
SGI: 0.92 (Revenue 186.5m / 202.7m)
TATA: -0.06 (NI -36.3m - CFO 7.97m) / TA 756.2m)
Beneish M = -2.73 (Cap -4..+1) = A

What is the price of CYRX shares?

As of November 02, 2026, the stock is trading at USD 17.29 with a total of 640,226 shares traded. Over the past week, the price has changed by -3.84%, over one month by -0.17%, over three months by +12.79% and over the past year by +92.11%.

Current recommended Stop Loss: 16.20 (which is 6.3% or 1.6 ATR below the current price).

Is CYRX a buy, sell or hold?

Cryoport has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy CYRX.

StrongBuy: 7
Buy: 1
Hold: 1
Sell: 0
StrongSell: 0

What are the forecasts/targets for the CYRX price?

Analysts Target Price	19.8	14.4%

Cryoport (CYRX) - Fundamental Data Overview as of 27 October 2026

Market Cap USD = 910.7m (910.7m USD * 1.0 USD.USD)
P/E Forward = 79.3651
P/S = 4.8842
P/B = 0.9822
P/EG = 62.1277
Revenue TTM = 186.5m USD
EBIT TTM = -28.9m USD
EBITDA TTM = -3.13m USD
Long Term Debt = 985k USD (from longTermDebt, last quarter)
Short Term Debt = 190.2m USD (from shortTermDebt, last quarter)
Debt = 277.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 45.2m
Net Debt = -119.5m USD (calculated: Debt 277.2m - CCE 396.7m)
Enterprise Value = 791.2m USD (910.7m + Debt 277.2m - CCE 396.7m)
Interest Coverage Ratio = -13.69 (Ebit TTM -28.9m / Interest Expense TTM 2.11m)
EV/FCF = -38.90x (Enterprise Value 791.2m / FCF TTM -20.3m)
FCF Yield = -2.57% (FCF TTM -20.3m / Enterprise Value 791.2m)
FCF Margin = -10.91% (FCF TTM -20.3m / Revenue TTM 186.5m)
Net Margin = -19.45% (Net Income TTM -36.3m / Revenue TTM 186.5m)
Gross Margin = 47.08% ((Revenue TTM 186.5m - Cost of Revenue TTM 98.7m) / Revenue TTM)
Gross Margin QoQ = 46.61% (prev 45.85%)
Tobins Q-Ratio = 1.05 (Enterprise Value 791.2m / Total Assets 756.2m)
Interest Expense / Debt = 0.76% (Interest Expense 2.11m / Debt 277.2m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -22.8m (EBIT -28.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.08 (Total Current Assets 460.2m / Total Current Liabilities 221.0m)
Debt / Equity = 0.56 (Debt 277.2m / totalStockholderEquity, last quarter 490.7m)
Debt / EBITDA = 38.19 (negative EBITDA) (Net Debt -119.5m / EBITDA -3.13m)
Debt / FCF = 5.88 (negative FCF - burning cash) (Net Debt -119.5m / FCF TTM -20.3m)
Total Stockholder Equity = 500.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.98% (Net Income -36.3m / Total Assets 756.2m)
RoE = -7.25% (Net Income TTM -36.3m / Total Stockholder Equity 500.4m)
RoCE = -5.76% (EBIT -28.9m / Capital Employed (Equity 500.4m + L.T.Debt 985k))
RoIC = -3.19% (negative operating profit) (NOPAT -22.8m / Invested Capital 716.1m)
WACC = 8.62% (E(910.7m)/V(1.19b) * Re(11.06%) + D(277.2m)/V(1.19b) * Rd(0.76%) * (1-Tc(0.21)))
Discount Rate = 11.06% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 84.06 | Cagr: 1.28%
[DCF] Fair Price = unknown (Cash Flow -20.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: -80.37 | Revenue CAGR: -7.73% | SUE: 0.10 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.17 | Chg30d=+0.00% | Revisions=-25% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.77 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=-13.5% | GrowthRev=+10.9%
EPS next Year (2027-12-31): EPS=-0.66 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+13.9% | GrowthRev=+10.1%
[Analyst] Revisions Ratio: +0% (up=2, down=2)